Overview
Australian clinical-stage biopharmaceutical company developing MDMA, psilocybin, and cannabis-derived therapeutics for mental health conditions with a data-driven clinical trial platform. They operate licensed clinics to generate real-world evidence for regulatory submissions.
More in Psychedelics
Latest industry news
ReVision Implant Secures โฌ4 Million to Advance Next-Generation Visual Neuroprosthetics
2026-07-25 ยท Funding
Flourish Emerges from Stealth with Bezos and Google Ventures Backing to Advance Neuroscience Therapeutics
2026-07-24 ยท Funding
Science Corp. Launches Prima BCI Implant in Europe, Bringing Vision Restoration to a New Market
2026-07-23 ยท Product
First Able-Bodied Individuals Receive Brain-Computer Implants in Landmark Expansion of BCI Eligibility
2026-07-22 ยท Research
Company details
Category
๐ Psychedelics
Location
Perth, Australia
Funding
Public ยท ASX
Website
emyria.com.auListed
2026-06-15
Is this your company?
Claim this listing to add your logo, full description, team, and products. Premium listings get featured placement.
Claim & upgrade listingAdvertise
Reach neurotech professionals
Newsletter sponsorships, featured listings, and sponsored articles.
View packages โ